株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Humira(潰瘍性大腸炎) - 予測と市場分析

Humira (Ulcerative Colitis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 300575
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Humira(潰瘍性大腸炎) - 予測と市場分析 Humira (Ulcerative Colitis) - Forecast and Market Analysis to 2022
出版日: 2014年02月28日 ページ情報: 英文 48 Pages
概要

2012年〜2022年の潰瘍性大腸炎(UC)治療薬市場は、Johnson & Johnson(Simponi)、武田薬品工業(Entyvio)の参入によって大幅な成長が予測され、主要国(米国、EU5ヶ国、日本、カナダ)において、生物製剤による治療を受ける患者数が増加すると見込まれています。また、UCのブロックバスター薬(Remicade、Humira)が米国で特許失効となるため、バイオシミラー(バイオ後続品)の発売が、市場に影響を与える可能性があります。

当レポートでは、UC治療薬であるHumiraについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
  • 症状

第4章 疾病の管理

  • 診断と治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Humira(adalimumab)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC346DFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Humira is considered a first-generation, first-line biologic therapy for the treatment of moderate to severe psoriasis. It is injected subcutaneously and is administered every two weeks (Humira package insert, 2011). Despite being the second anti-TNF to launch for UC, its rise to the top of the anti-TNF class is due, in part, to its SC administration, along with AbbVie's extensive marketing experience. Humira is marketed by AbbVie in the US and Europe, and by Eisai in Japan.

Scope

  • Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Humira including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Humira for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Canada.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Humira performance
  • Obtain sales forecast for Humira from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Canada)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Humira (adalimumab)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed UC Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. Primary Research. Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: Leading Treatments for UC, 2014
  • Table 8: Product Profile - Humira
  • Table 9: Humira Efficacy in the ULTRA 2 Trial
  • Table 10: Product Efficacy Comparison - Humira vs. Remicade
  • Table 11: Humira SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Humira, 2012-2022
  • Table 13: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
Back to Top